Aligos Therapeutics Inc. announced positive data from multiple presentations at the American Association for the Study of Liver Disease's The Liver Meeting® 2025, held November 7-11, 2025, in Washington, D.C. The company highlighted clinical results for pevifoscorvir sodium, a capsid assembly modulator under investigation for the treatment of chronic hepatitis B virus (HBV) infection. An oral presentation and several posters detailed 96-week treatment and post-treatment data, suggesting pevifoscorvir sodium demonstrates potent suppression of HBV DNA and sustained reduction of HBV antigen levels in treatment-naive or currently-not-treated subjects. The results were presented by Professor Man-Fung Yuen of the University of Hong Kong. Aligos also presented preclinical data on other investigational agents, including the capsid assembly modulator ALG-001075, which prevents cccDNA formation and HBV DNA integration in vitro. The company indicated ongoing progress in its HBV antisense oligonucleotide $(ASO)$ program.